NextCure Inc (NXTC)
NASDAQ:NXTC
Want to see NXTC full AI Analyst Report?
Top Page
NextCure
(NASDAQ:NXTC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▼(-74.51% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily held down by weak financial performance (no revenue, large losses, and negative cash flow with declining equity) and a bearish technical setup (price far below key moving averages and negative MACD). Positive Phase 1 clinical data provides an offsetting catalyst, but the finite cash runway and lack of profitability keep the overall profile speculative.
Positive Factors
Clinical-stage efficacy
A 55% objective response rate in heavily pretreated gynecologic cancers provides durable proof-of-concept for SIM0505, materially de-risking the program versus preclinical stages. This clinical validation supports potential partnerships, smoother enrollment in later trials, and greater probability of future licensing or commercialization revenue.
Negative Factors
No product revenue
Absence of product sales leaves the company structurally dependent on external financing and collaboration deals to fund operations. Until regulatory approvals or commercial partnerships produce recurring revenue, the business lacks internally generated cash flows, keeping long-term sustainability contingent on successful trials and capital markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage efficacy
A 55% objective response rate in heavily pretreated gynecologic cancers provides durable proof-of-concept for SIM0505, materially de-risking the program versus preclinical stages. This clinical validation supports potential partnerships, smoother enrollment in later trials, and greater probability of future licensing or commercialization revenue.
Read all positive factors
NextCure (NXTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.28M
Dividend YieldN/A
Average Volume (3M)37.58K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth10.17%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-19.07
Shares Outstanding3,612,096
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.82
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$25.00Price Target Upside82.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-9.07
Revenue Forecast (FY)N/A
NextCure Business Overview & Revenue Model
Company Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, whi...
How the Company Makes Money
NextCure’s primary source of cash flows is funding from financing activities (e.g., issuing equity or other capital-raising transactions) because it is a clinical-stage company and does not have product sales from approved therapies. Operating rev...
NextCure Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -283.00K | -2.19M | -2.87M | 0.00 | 0.00 | 0.00 |
| EBITDA | -53.96M | -55.43M | -54.34M | -63.95M | -71.78M | -66.59M |
| Net Income | -54.66M | -55.84M | -55.65M | -62.72M | -74.73M | -69.39M |
Balance Sheet | ||||||
| Total Assets | 37.98M | 50.18M | 80.86M | 128.04M | 184.16M | 242.39M |
| Cash, Cash Equivalents and Short-Term Investments | 29.74M | 41.82M | 68.62M | 108.30M | 159.91M | 219.59M |
| Total Debt | 3.88M | 4.15M | 5.95M | 6.61M | 7.12M | 0.00 |
| Total Liabilities | 11.26M | 15.24M | 15.39M | 13.62M | 16.63M | 9.00M |
| Stockholders Equity | 26.72M | 34.94M | 65.47M | 114.42M | 167.53M | 233.39M |
Cash Flow | ||||||
| Free Cash Flow | -49.98M | -49.61M | -41.28M | -53.79M | -56.00M | -59.60M |
| Operating Cash Flow | -49.98M | -49.61M | -40.80M | -52.97M | -53.89M | -57.24M |
| Investing Cash Flow | 19.76M | 25.56M | 55.31M | 39.27M | 67.98M | 36.60M |
| Financing Cash Flow | 23.56M | 22.31M | 144.00K | 154.00K | 200.00K | -3.27M |
NextCure Technical Analysis
Negative
13.73
Price Trends
9.77
Negative
11.09
Negative
9.98
Negative
Market Momentum
-1.52
Positive
23.06
Positive
7.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXTC, the sentiment is Negative. The current price of 13.73 is above the 20-day moving average (MA) of 8.39, above the 50-day MA of 9.77, and above the 200-day MA of 9.98, indicating a bearish trend. The MACD of -1.52 indicates Positive momentum. The RSI at 23.06 is Positive, neither overbought nor oversold. The STOCH value of 7.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NXTC.
NextCure Risk Analysis
NextCure disclosed 70 risk factors in its most recent earnings report. NextCure reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NextCure Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $14.00M | -1.00 | -229.48% | ― | ― | 83.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $221.30M | -0.50 | 359.80% | ― | ― | -3629.03% | |
46 Neutral | $12.28M | -0.33 | -186.96% | ― | ― | 10.17% | |
46 Neutral | $7.95M | -9.58 | -9.02% | ― | ― | -1979.68% |
* Healthcare Sector Average
NXTC
NextCure
3.40
-2.28
-40.14%
NERV
Minerva Neurosciences
4.75
3.00
170.66%
MTVA
MetaVia
2.71
-4.68
-63.33%
APM
Aptorum Group
0.98
-0.06
-6.15%
NextCure Corporate Events
Business Operations and StrategyProduct-Related Announcements
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data
Positive
Jun 1, 2026
On June 1, 2026, NextCure reported positive Phase 1 dose-escalation data for its CDH6-targeting antibody-drug conjugate SIM0505 in heavily pretreated patients with advanced gynecologic cancers, presented at the ASCO 2026 meeting in Chicago. In ova...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.